Chargement en cours...
Safety of switching between rituximab biosimilars in onco-hematology
Comparable clinical efficacy and safety of the reference rituximab (MABTHERA) and its biosimilars has been established in randomized trials. However, safety concerns are often raised when switching from reference to biosimilar products and between different biosimilars. In this prospective observati...
Enregistré dans:
| Publié dans: | Sci Rep |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group UK
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7966361/ https://ncbi.nlm.nih.gov/pubmed/33727667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85563-1 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|